Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1966 4
1967 1
1968 2
1969 2
1970 2
1974 1
1975 5
1977 2
1978 1
1979 2
1980 2
1981 4
1982 6
1983 5
1985 2
1986 3
1987 5
1988 2
1989 2
1990 2
1991 2
1992 1
1993 4
1994 2
1995 4
1996 4
1997 4
1998 2
1999 3
2000 5
2001 3
2002 4
2003 5
2004 7
2005 7
2006 3
2007 7
2008 5
2009 9
2010 6
2011 5
2012 11
2013 13
2014 14
2015 7
2016 11
2017 14
2018 12
2019 13
2020 13
2021 15
2022 21
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Results by year

Filters applied: . Clear all
Page 1
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y, Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T. Yamada S, et al. Among authors: murai a. Cancer Immunol Immunother. 2023 Jul;72(7):2057-2065. doi: 10.1007/s00262-023-03388-5. Epub 2023 Feb 16. Cancer Immunol Immunother. 2023. PMID: 36795123
GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T, Tsukahara T, Kanaseki T, Shinohara N, Torigoe T. Miyata H, et al. Among authors: murai a. Cancer Immunol Immunother. 2022 Apr;71(4):795-806. doi: 10.1007/s00262-021-03025-z. Epub 2021 Aug 18. Cancer Immunol Immunother. 2022. PMID: 34405274
Total synthesis of pectenotoxin-2.
Fujiwara K, Suzuki Y, Koseki N, Aki Y, Kikuchi Y, Murata S, Yamamoto F, Kawamura M, Norikura T, Matsue H, Murai A, Katoono R, Kawai H, Suzuki T. Fujiwara K, et al. Among authors: murai a. Angew Chem Int Ed Engl. 2014 Jan 13;53(3):780-4. doi: 10.1002/anie.201308502. Epub 2013 Nov 29. Angew Chem Int Ed Engl. 2014. PMID: 24288200
Rewriting the Central Dogma with Synthetic Genetic Polymers.
Saito-Tarashima N, Murai A, Minakawa N. Saito-Tarashima N, et al. Among authors: murai a. Chem Pharm Bull (Tokyo). 2022;70(5):310-315. doi: 10.1248/cpb.c21-00960. Chem Pharm Bull (Tokyo). 2022. PMID: 35491185 Free article.
Enhanced nerve autograft using stromal vascular fraction.
Tada K, Nakada M, Matsuta M, Murai A, Hayashi K, Tsuchiya H. Tada K, et al. Among authors: murai a. Eur J Orthop Surg Traumatol. 2021 Jan;31(1):183-188. doi: 10.1007/s00590-020-02758-4. Epub 2020 Aug 9. Eur J Orthop Surg Traumatol. 2021. PMID: 32776214
Fusion with type 2 macrophages induces melanoma cell heterogeneity that potentiates immunological escape from cytotoxic T lymphocytes.
Minowa T, Hirohashi Y, Murata K, Sasaki K, Handa T, Nakatsugawa M, Mizue Y, Murai A, Kubo T, Kanaseki T, Tsukahara T, Iwabuchi S, Hashimoto S, Ishida-Yamamoto A, Uhara H, Torigoe T. Minowa T, et al. Among authors: murai a. J Pathol. 2023 Jul;260(3):304-316. doi: 10.1002/path.6083. Epub 2023 May 3. J Pathol. 2023. PMID: 37138382
287 results